Copertina

sTREM2 in discordant CSF Aβ42 and p‐tau181

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Danni Li, William G. Mantyh, Lu Men, Ishika Jain, Matthew Glittenberg, Binchong An, Lin Zhang, Ling Li
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Clinical and neuropathological associations of plasma Aβ42/Aβ40, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders
di: Binita Rajbanshi, et al.
Pubblicazione: (2025)

Clinical utility of CSF Aβ38 in Japanese research and clinical cohorts
di: Tamao Tsukie, et al.
Pubblicazione: (2025)

Digital cognition plus plasma p‐Tau217 and Aβ42/40 powerfully predict Alzheimer's progression
di: Ahmet Begde, et al.
Pubblicazione: (2026)

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
di: Lara Blömeke, et al.
Pubblicazione: (2024)

Correction to “Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology”
Pubblicazione: (2024)

Diagnostic utility of plasma p‐tau217 differs by Alzheimer's disease tau‐based subtypes
di: Seyed Hani Hojjati, et al.
Pubblicazione: (2025)

Clinical and demographic factors modify the association between plasma phosphorylated tau‐181 and cognition
di: Corey J. Bolton, et al.
Pubblicazione: (2024)

Factors associated with discordant visual and quantitative amyloid PET results
di: Jasmin E Guevara, et al.
Pubblicazione: (2026)

Marital dissolution and cognition: The mediating effect of Aβ neuropathology
di: Avinash Chandra, et al.
Pubblicazione: (2024)

Plasma p‐tau217 and APOE genotype: Prodromal Alzheimer's disease staging
di: Ann M. Stowe, et al.
Pubblicazione: (2026)

Interchangeability of CSF and PET to identify Alzheimer's disease pathology
di: Samantha C. Burnham, et al.
Pubblicazione: (2026)

Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting
di: Rebecca Z. Rousset, et al.
Pubblicazione: (2024)

Comparison of three plasma p‐tau217 assays to detect PET‐confirmed Alzheimer's pathologies
di: Sayo Matsuura, et al.
Pubblicazione: (2026)

Plasma p‐tau217 for Alzheimer's disease diagnosis: a memory clinic implementation approach
di: Giorgia Brodini, et al.
Pubblicazione: (2026)

Inter‐scanner Aβ‐PET harmonization using barrel phantom spatial resolution matching
di: Gihan P. Ruwanpathirana, et al.
Pubblicazione: (2024)

Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples
di: Anna E. Mammel, et al.
Pubblicazione: (2025)

Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
di: Adam H. Dyer, et al.
Pubblicazione: (2025)

Plasma p‐tau217 and cognitive impairment: Evaluating biomarker equity across racial/ethnic groups in HABS‐HD
di: Cellas A. Hayes, et al.
Pubblicazione: (2026)

Clinical performance of scalable automated p‐tau 217 multi‐analyte algorithmic blood test with reduced intermediate zone using multiplexed digital immunoassay
di: David H. Wilson, et al.
Pubblicazione: (2025)

Plasma biomarker‐informed brain topology for cognitive resilience: applications in non‐pharmacological interventions concerning cognitive aging
di: Meishan Ai, et al.
Pubblicazione: (2026)

Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
di: Qi Huang, et al.
Pubblicazione: (2025)

Hallucinations and delusions are associated with elevated tau PET signal independent of age, clinical severity, and amyloid burden
di: Aubrey S Johnson, et al.
Pubblicazione: (2026)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
di: Cassandra Marotta, et al.
Pubblicazione: (2025)

Survey among experts on the future role of tau‐PET in clinical practice and trials
di: Marie R. Vermeiren, et al.
Pubblicazione: (2024)

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET‐MR
di: Hossein Moein Taghavi, et al.
Pubblicazione: (2024)

Identifying cognitive test scores associated with early tau burden in Alzheimer's disease
di: Caitlin M. Terao, et al.
Pubblicazione: (2025)

Cross‐sectional study of plasma phosphorylated tau 217 in persons without dementia
di: Toni T. Saari, et al.
Pubblicazione: (2025)

Resistance and resilience to tau pathology in Alzheimer's disease: Effects of age, sex, and APOE alleles
di: Yury Loika, et al.
Pubblicazione: (2024)

Associations of plasma phosphorylated tau217 with cognitive impairment and brain microstructural alterations in Alzheimer's disease
di: Miguel Ángel Rivas‐Fernández, et al.
Pubblicazione: (2026)

Clinical validation of the Lilly SP‐X P‐tau217 assay: Performance in underrepresented cohorts
di: Michael E. Hodsdon, et al.
Pubblicazione: (2025)

Explaining variability in early stages of [18F]‐flortaucipir tau‐PET binding: Focus on sex differences
di: Dario Bachmann, et al.
Pubblicazione: (2024)

Association of item‐level responses to cognitive function index with tau pathology and hippocampal volume in the A4 Study
di: Idris Demirsoy, et al.
Pubblicazione: (2025)

Investigating the amyloid–tau–neurodegeneration framework in Alzheimer's disease using semi‐supervised multimodal imaging data fusion
di: You Cheng, et al.
Pubblicazione: (2026)

Body composition and plasma total‐tau, neurofilament light chain, and amyloid‐β: A population‐based study
di: Tosca O. E. de Crom, et al.
Pubblicazione: (2024)

Classifying mild cognitive impairment from normal cognition: fMRI complexity matches tau PET performance
di: Kay Jann, et al.
Pubblicazione: (2025)

P‐tau217 testing impact on intended management of patients presenting with cognitive impairment: A randomized clinical utility study
di: Samantha C. Burnham, et al.
Pubblicazione: (2025)

Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
di: Annibale Antonioni, et al.
Pubblicazione: (2025)

Association of arterial structure and function with incident cardiovascular diseases and cognitive decline
di: Caroline Robert, et al.
Pubblicazione: (2025)

The impact of amyloid beta burden on white matter dysfunction and associated transcriptomic signatures in cognitively normal elderly individuals
di: Ziyun Li, et al.
Pubblicazione: (2025)

Associations of plasma p‐Tau217 with cognitive domain performance in clinically unimpaired participants: Evidence from HABS‐HD
di: Zara Najmi, et al.
Pubblicazione: (2026)